W
William R. Moore
Researcher at Durham University
Publications - 29
Citations - 627
William R. Moore is an academic researcher from Durham University. The author has contributed to research in topics: Prostate cancer & Abiraterone acetate. The author has an hindex of 9, co-authored 29 publications receiving 523 citations.
Papers
More filters
Journal ArticleDOI
Design and optimization of highly-selective fungal CYP51 inhibitors
William J. Hoekstra,Edward P. Garvey,William R. Moore,Stephen W. Rafferty,Christopher M. Yates,Robert J. Schotzinger +5 more
TL;DR: Rationally-designed, broad-spectrum antifungal agents that are more selective for the target fungal enzyme, CYP51, than related human CYP enzymes such as CYP3A4 are described.
Journal ArticleDOI
The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme
Andrew G. S. Warrilow,Claire M. Hull,Josie E. Parker,Edward P. Garvey,W. J. Hoekstra,William R. Moore,R. J. Schotzinger,Diane E. Kelly,Steven L. Kelly +8 more
TL;DR: VT-1161 potently inhibited Candida albicans CYP51 and culture growth but did not inhibit human CYP 51, demonstrating a >2,000-fold selectivity, which strongly supports the potential utility of VT- 1161 in the treatment of Candida infections.
Journal ArticleDOI
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Paul Toren,Soojin Kim,Steven Pham,Azzra Mangalji,Hans Adomat,Emma S. Tomlinson Guns,Amina Zoubeidi,William R. Moore,Martin E. Gleave +8 more
TL;DR: Preclinical results suggest greater suppression of the AR axis with VT-464 than ABI that is likely due to both superior selective suppression of androgen synthesis and AR antagonism.
Journal ArticleDOI
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Stephen W. Rafferty,Joel R. Eisner,William R. Moore,Robert J. Schotzinger,William J. Hoekstra +4 more
TL;DR: Rationally-designed, CYP17 lyase-selective inhibitors that could prove safer and more effective than abiraterone are described, potentially applicable to the design of new and moreeffective metalloenzyme inhibitor treatments for a broad array of diseases.
Journal ArticleDOI
VT-1161 Dosed Once Daily or Once Weekly Exhibits Potent Efficacy in Treatment of Dermatophytosis in a Guinea Pig Model
Edward P. Garvey,W. J. Hoekstra,William R. Moore,R. J. Schotzinger,Lisa Long,Mahmoud A. Ghannoum +5 more
TL;DR: Clinical development of VT-1161 for the oral treatment of onychomycosis using either once-daily or once-weekly dosing regimens is strongly supported.